Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at Cincinnati Children's Medical Center, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypotheses of this NINJA NGAL study are that (1) urine NGAL is highly sensitive to detect NTMx-associated AKI, and (2) Bedside test of urine from high risk NTMx-exposed patients are adequate and reliable compared to urine NGAL measured from the clinical platform.
Study Type
OBSERVATIONAL
Enrollment
134
Children's of Alabama
Birmingham, Alabama, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Number of Patients With Nephrotoxic Medication Associated AKI Detected by Urinary NGAL
AKI, defined as a 50% rise in serum Creatinine over baseline or a 0.3 mg/dL rise within 48 hours, will be first detected by a rise in Urinary NGAL
Time frame: 9 Days
Point of Care NGAL Reliability Compared to Clinical Urinary NGAL
A POC urinary NGAL will be determined from a colorimetric assay that determines risk of AKI, which will later be compared to NGAL values from the clinical assay
Time frame: 7 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.